RORγ agonist LYC-55716 is being tested in the clinic for advanced or metastatic cancer in a Phase I/II trial (NCT03396497), and in combination with pembrolizumab for NSCLC in a Phase I trial (NCT02929862) [19]. Here, RORC is linked to metastatic malignant neoplasm.